56d8ca4163648f090dc7fdfede8dd5c3 293202.pdf 4e404a4f73b4c3e3c196ce1755b66c7498dbc611 293202.pdf ad9779feed315229fa22cfddef4e48b2cde627c04b2dd0c068f69697753f61a6 293202.pdf Title: Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B Subject: Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d’Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects. Keywords: complex cutaneous leishmaniasis; cutaneous leishmaniasis; liposomal amphotericin B; leishmania; systemic therapy Author: Maria Ubals, Pau Bosch-Nicolau, Adrián Sánchez-Montalvá, Fernando Salvador, Gloria Aparicio-Español, Elena Sulleiro, Aroa Silgado, Antoni Soriano-Arandes, Maria Espiau, Berta Ferrer, Diana Pou, Begoña Treviño, Israel Molina and Vicente García-Patos Creator: LaTeX with hyperref Producer: pdfTeX-1.40.21 CreationDate: Tue Sep 28 10:45:38 2021 CEST ModDate: Tue Sep 28 10:56:55 2021 CEST Custom Metadata: no Metadata Stream: no Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 9 Encrypted: no Page size: 595.276 x 841.89 pts (A4) Page rot: 0 File size: 944471 bytes Optimized: no PDF version: 1.7 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- SSNIUI+VnURWPalladioL-Bold Type 1 Custom yes yes no 10 0 WKDIFV+VnURWPalladioL Type 1 Custom yes yes no 15 0 EMYAGZ+URWPalladioL-Ital Type 1 Custom yes yes no 19 0 LSNYFF+URWPalladioL-Bold Type 1 Custom yes yes no 24 0 HTZRGU+URWPalladioL-Roma Type 1 Custom yes yes no 28 0 UXHOAG+TimesNewRomanPS-BoldItalicMT Type 1C WinAnsi yes yes no 37 0 MCBCCI+SourceSansRoman-Regular Type 1C Custom yes yes no 59 0 MCBCCM+SourceSansRoman.613wght Type 1C Custom yes yes no 63 0 MCBCCO+SourceSansRoman-Bold Type 1C Custom yes yes no 67 0 CKBPVA+EURM10 Type 1 Builtin yes yes no 79 0 CLNKEB+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 96 0 CLNKED+PalatinoLinotype TrueType WinAnsi yes yes no 99 0 CLNKEF+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 102 0 CLNNLD+Calibri,Bold CID TrueType Identity-H yes yes yes 105 0 CLNKEB+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 123 0 CLNKED+PalatinoLinotype TrueType WinAnsi yes yes no 126 0 CLNKEF+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 129 0 PDTLUH+CMSY10 Type 1 Builtin yes yes no 139 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2024-06-07 02:36:59 CEST RepresentationInformation: 293202.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2024-06-06 08:45:51 CEST Size: 944471 Format: PDF Version: 1.7 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 251 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Introduction Destination: section.1 Item: Title: Results Destination: section.2 Children: Item: Title: Demographic and Epidemiologic Characteristics Destination: subsection.2.1 Item: Title: Diagnostic Methods and Classification Destination: subsection.2.2 Item: Title: Treatment Outcomes Destination: subsection.2.3 Item: Title: Treatment Safety Destination: subsection.2.4 Item: Title: Discussion Destination: section.3 Item: Title: Materials and Methods Destination: section.4 Children: Item: Title: Patients’ Selection and Data Collection Destination: subsection.4.1 Item: Title: Treatment Criteria Destination: subsection.4.2 Item: Title: Outcome Criteria Destination: subsection.4.3 Item: Title: Statistical Analysis Destination: subsection.4.4 Item: Title: Ethics Statement or Compliance with Ethical Standards Destination: subsection.4.5 Item: Title: Conclusions Destination: section.5 Item: Title: References Destination: section.5 Info: Title: Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B Author: Maria Ubals, Pau Bosch-Nicolau, Adrián Sánchez-Montalvá, Fernando Salvador, Gloria Aparicio-Español, Elena Sulleiro, Aroa Silgado, Antoni Soriano-Arandes, Maria Espiau, Berta Ferrer, Diana Pou, Begoña Treviño, Israel Molina and Vicente García-Patos Subject: Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d’Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects. Keywords: complex cutaneous leishmaniasis; cutaneous leishmaniasis; liposomal amphotericin B; leishmania; systemic therapy Creator: LaTeX with hyperref Producer: pdfTeX-1.40.21 CreationDate: Tue Sep 28 10:45:38 CEST 2021 ModDate: Tue Sep 28 10:56:55 CEST 2021 ID: 0xee294d3ad65d87686d8f04c6e8eac512, 0xee294d3ad65d87686d8f04c6e8eac512 Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: EMYAGZ+URWPalladioL-Ital FontSubset: true FirstChar: 2 LastChar: 122 FontDescriptor: FontName: EMYAGZ+URWPalladioL-Ital Flags: Symbolic FontBBox: -170, -305, 1010, 941 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: LSNYFF+URWPalladioL-Bold FontSubset: true FirstChar: 2 LastChar: 241 FontDescriptor: FontName: LSNYFF+URWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: SSNIUI+VnURWPalladioL-Bold FontSubset: true FirstChar: 161 LastChar: 189 FontDescriptor: FontName: SSNIUI+VnURWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: PDTLUH+CMSY10 FontSubset: true FirstChar: 21 LastChar: 21 FontDescriptor: FontName: PDTLUH+CMSY10 Flags: Symbolic FontBBox: -29, -960, 1116, 775 FontFile: true Font: BaseFont: HTZRGU+URWPalladioL-Roma FontSubset: true FirstChar: 2 LastChar: 241 FontDescriptor: FontName: HTZRGU+URWPalladioL-Roma Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: WKDIFV+VnURWPalladioL FontSubset: true FirstChar: 160 LastChar: 226 FontDescriptor: FontName: WKDIFV+VnURWPalladioL Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: CKBPVA+EURM10 FontSubset: true FirstChar: 11 LastChar: 11 FontDescriptor: FontName: CKBPVA+EURM10 Flags: Symbolic FontBBox: -32, -243, 1060, 720 FontFile: true Pages: Page: Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 35, 759, 168, 795 Annotation: Subtype: Link Rect: 515, 759, 560, 795 Annotation: Subtype: Link Rect: 111, 660, 122, 673 Annotation: Subtype: Link Rect: 225, 660, 236, 673 Annotation: Subtype: Link Rect: 372, 660, 383, 673 Annotation: Subtype: Link Rect: 235, 647, 246, 661 Annotation: Subtype: Link Rect: 439, 647, 450, 661 Annotation: Subtype: Link Rect: 520, 647, 531, 661 Annotation: Subtype: Link Rect: 154, 634, 165, 648 Annotation: Subtype: Link Rect: 246, 634, 257, 648 Annotation: Subtype: Link Rect: 458, 634, 469, 648 Annotation: Subtype: Link Rect: 113, 406, 154, 415 Annotation: Subtype: Link Rect: 35, 394, 150, 403 Annotation: Subtype: Link Rect: 35, 162, 97, 184 Annotation: Subtype: Link Rect: 153, 89, 154, 98 Annotation: Subtype: Link Rect: 35, 77, 147, 86 Annotation: Subtype: Link Rect: 470, 105, 477, 114 ActionDest: 143 Annotation: Subtype: Link Rect: 478, 105, 485, 114 ActionDest: 143 Annotation: Subtype: Link Rect: 122, 17, 283, 28 Annotation: Subtype: Link Rect: 398, 17, 558, 28 Annotation: Subtype: Link Rect: 35, 506, 87, 525 Page: Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 226, 649, 233, 658 ActionDest: 143 Annotation: Subtype: Link Rect: 242, 586, 249, 595 ActionDest: 143 Annotation: Subtype: Link Rect: 441, 561, 448, 570 ActionDest: 143 Annotation: Subtype: Link Rect: 371, 523, 378, 532 ActionDest: 143 Annotation: Subtype: Link Rect: 312, 485, 319, 495 ActionDest: 143 Annotation: Subtype: Link Rect: 456, 448, 463, 457 ActionDest: 143 Annotation: Subtype: Link Rect: 467, 448, 473, 457 ActionDest: 146 Annotation: Subtype: Link Rect: 453, 410, 465, 419 ActionDest: 146 Annotation: Subtype: Link Rect: 466, 410, 478, 419 ActionDest: 146 Annotation: Subtype: Link Rect: 538, 168, 545, 180 ActionDest: 83 Annotation: Subtype: Link Rect: 476, 105, 483, 117 ActionDest: 83 Page: Sequence: 3 Annotations: Annotation: Subtype: Link Rect: 552, 77, 559, 89 ActionDest: 86 Page: Sequence: 4 Annotations: Annotation: Subtype: Link Rect: 533, 179, 540, 191 ActionDest: 113 Annotation: Subtype: Link Rect: 457, 141, 464, 153 ActionDest: 113 Page: Sequence: 5 Annotations: Annotation: Subtype: Link Rect: 198, 120, 210, 129 ActionDest: 146 Annotation: Subtype: Link Rect: 498, 83, 510, 92 ActionDest: 146 Page: Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 329, 672, 341, 681 ActionDest: 146 Annotation: Subtype: Link Rect: 341, 672, 353, 681 ActionDest: 146 Annotation: Subtype: Link Rect: 308, 559, 320, 568 ActionDest: 146 Annotation: Subtype: Link Rect: 544, 471, 556, 480 ActionDest: 146 Annotation: Subtype: Link Rect: 495, 459, 507, 468 ActionDest: 146 Annotation: Subtype: Link Rect: 278, 396, 290, 405 ActionDest: 146 Annotation: Subtype: Link Rect: 446, 371, 453, 380 ActionDest: 143 Annotation: Subtype: Link Rect: 454, 371, 466, 380 ActionDest: 146 Annotation: Subtype: Link Rect: 317, 346, 324, 355 ActionDest: 143 Annotation: Subtype: Link Rect: 309, 283, 321, 292 ActionDest: 146 Annotation: Subtype: Link Rect: 531, 283, 543, 292 ActionDest: 146 Annotation: Subtype: Link Rect: 543, 283, 555, 292 ActionDest: 146 Annotation: Subtype: Link Rect: 469, 270, 481, 279 ActionDest: 146 Annotation: Subtype: Link Rect: 550, 145, 557, 154 ActionDest: 143 Page: Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 276, 631, 288, 640 ActionDest: 146 Annotation: Subtype: Link Rect: 503, 417, 510, 426 ActionDest: 143 Page: Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 419, 595, 560, 606 Annotation: Subtype: Link Rect: 166, 583, 284, 594 Annotation: Subtype: Link Rect: 423, 224, 460, 234 Annotation: Subtype: Link Rect: 466, 224, 502, 234 Annotation: Subtype: Link Rect: 519, 211, 557, 222 Annotation: Subtype: Link Rect: 59, 201, 95, 211 Annotation: Subtype: Link Rect: 380, 188, 417, 199 Annotation: Subtype: Link Rect: 477, 154, 515, 165 Annotation: Subtype: Link Rect: 521, 154, 557, 165 Annotation: Subtype: Link Rect: 118, 132, 155, 142 Annotation: Subtype: Link Rect: 478, 108, 515, 119 Annotation: Subtype: Link Rect: 280, 73, 317, 84 Annotation: Subtype: Link Rect: 491, 62, 528, 73 Page: Sequence: 9 Annotations: Annotation: Subtype: Link Rect: 415, 709, 452, 720 Annotation: Subtype: Link Rect: 213, 675, 250, 686 Annotation: Subtype: Link Rect: 388, 652, 426, 663 Annotation: Subtype: Link Rect: 95, 630, 133, 640 Annotation: Subtype: Link Rect: 373, 571, 411, 582 Annotation: Subtype: Link Rect: 213, 537, 250, 548 Annotation: Subtype: Link Rect: 293, 514, 330, 525 Annotation: Subtype: Link Rect: 183, 480, 220, 490 Annotation: Subtype: Link Rect: 226, 480, 262, 490 Annotation: Subtype: Link Rect: 454, 456, 491, 467 Annotation: Subtype: Link Rect: 497, 456, 533, 467 Annotation: Subtype: Link Rect: 477, 433, 515, 444 Annotation: Subtype: Link Rect: 521, 433, 557, 444 Annotation: Subtype: Link Rect: 59, 400, 97, 410 Annotation: Subtype: Link Rect: 103, 400, 139, 410 Annotation: Subtype: Link Rect: 202, 376, 239, 387 Annotation: Subtype: Link Rect: 245, 376, 281, 387 Annotation: Subtype: Link Rect: 255, 353, 292, 364 Annotation: Subtype: Link Rect: 298, 353, 334, 364 Checksum: 95854737 Type: CRC32 Checksum: 56d8ca4163648f090dc7fdfede8dd5c3 Type: MD5 Checksum: 4e404a4f73b4c3e3c196ce1755b66c7498dbc611 Type: SHA-1 Checksum: ad9779feed315229fa22cfddef4e48b2cde627c04b2dd0c068f69697753f61a6 Type: SHA-256